This company is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Humanigen Salute del bilancio
Salute finanziaria criteri di controllo 1/6
Humanigen has a total shareholder equity of $-49.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.1M and $54.8M respectively.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$3.10m |
| Patrimonio netto | -US$49.72m |
| Totale passività | US$54.84m |
| Totale attività | US$5.12m |
Aggiornamenti recenti sulla salute finanziaria
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Analisi della posizione finanziaria
Passività a breve termine: HGEN.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passività a lungo termine: HGEN.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: HGEN.Q is debt free.
Riduzione del debito: HGEN.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: Insufficient data to determine if HGEN.Q has enough cash runway based on its current free cash flow.
Previsione Cash Runway: Insufficient data to determine if HGEN.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.